{
    "nctId": "NCT00934895",
    "briefTitle": "Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Adv. or Metastatic Breast Ca",
    "officialTitle": "Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Advanced or Metastatic Breast Cancer. A Study of the Cancer Institute of New Jersey Oncology Group (CINJOG)",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1, PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 27,
    "primaryOutcomeMeasure": "To Determine the Maximum Tolerated Dose (MTD) of RAD001 in Combination of Weekly Abraxane and Determine the Phase II Dose of RAD001.",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed breast cancer\n\n  * Locally recurrent or metastatic disease\n  * Not amenable to surgery or radiotherapy\n* HER2/neu-negative disease\n* Has \u2265 1 measurable lesion, as defined by RECIST criteria\n\n  * No non-measurable lesions (e.g., pleural effusion or ascites) other than bone metastases\n\n    * Bone metastases as the sole site of disease allowed provided there are \u2265 2 lytic bone lesions by x-ray, CT scan, or MRI\n  * Lesions irradiated in the advanced setting are not considered sites of measurable disease unless clear tumor progression has been documented in these lesions since the completion of radiotherapy\n* No bilateral diffuse lymphangitis carcinomatosa of the lung (\\> 50% of lung involvement) or evidence of liver metastases estimated as involving \\> one third of the liver by sonogram and/or CT scan\n* No unstable CNS metastases\n* Hormone receptor status not specified\n\nPATIENT CHARACTERISTICS:\n\n* Menopausal status not specified\n* ECOG performance status 0-2\n* Life expectancy \u2265 3 months\n* ANC \u2265 1,500/mm\\^3\n* Platelet count \u2265 100,000/mm\\^3\n* Hemoglobin \\> 9 g/dL\n* Serum bilirubin \u2264 1.5 times upper limit of normal (ULN)\n* ALT and AST \u2264 2.5 times ULN (\u2264 5 times ULN in patients with liver metastases)\n* INR \\< 1.5 times ULN\n* Serum creatinine \u2264 1.5 mg/dL\n* Fasting serum cholesterol \u2264 300 mg/dL (or 7.75 mmol/L) (levels outside this threshold allowed provided statin therapy is initiated)\n* Fasting triglycerides \u2264 2.5 times ULN (levels outside this threshold allowed provided statin therapy is initiated)\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n\n  * Oral, implantable, or injectable contraceptives are not considered effective contraception\n* No ascites or encephalopathy due to liver disease\n* No neuropathy \u2265 grade 2\n* No impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of everolimus, including any of the following:\n\n  * Ulcerative disease\n  * Uncontrolled nausea, vomiting, or diarrhea\n  * Malabsorption syndrome\n* No active, bleeding diathesis\n* No known HIV seropositivity\n* No known hypersensitivity to everolimus or sirolimus (rapamycin), paclitaxel albumin-stabilized nanoparticle formulation, or lactose\n* No history of noncompliance to medical regimens\n* No severe and/or uncontrolled medical condition or other condition that could affect study participation, including any of the following:\n\n  * Unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction within the past 6 months, or serious uncontrolled cardiac arrhythmia\n  * Severely impaired lung function\n  * Active (acute or chronic) or uncontrolled infections or disorders\n  * Nonmalignant medical illnesses that are uncontrolled or whose control may be jeopardized by study treatment\n  * Liver disease (e.g., cirrhosis, chronic active hepatitis, or chronic persistent hepatitis)\n* No other malignancies within the past 5 years, except curatively treated carcinoma in situ of the cervix or nonmelanoma skin cancer\n\nPRIOR CONCURRENT THERAPY:\n\n* Prior systemic endocrine therapy for advanced breast cancer allowed\n* No prior chemotherapy for advanced breast cancer\n\n  * Prior adjuvant chemotherapy allowed\n* No prior small bowel resection\n* More than 5 days since prior strong CYP3A inhibitors or inducers (e.g., rifabutin, rifampin, clarithromycin, ketoconazole, itraconazole, voriconazole, ritonavir, or telithromycin)\n* More than 30 days since prior radiotherapy and recovered (alopecia allowed)\n* Prior localized radiotherapy for analgesic purposes allowed provided radiotherapy has been completed and the patient's condition is stabilized\n* No prior radiotherapy to \u2265 25% of the bone marrow\n* More than 30 days since prior investigational drugs\n* More than 1 week since prior and no concurrent immunization with attenuated live vaccines\n* No concurrent oral anti-vitamin K medication, except low-dose coumadin\n* No concurrent systemic steroids or other immunosuppressive agents as chronic therapy\n\n  * Topical applications, inhaled sprays, eye drops, or local injections allowed\n  * A short duration (\\< 2 weeks) of systemic corticosteroids allowed\n* No concurrent hormone replacement therapy, topical estrogens (including any intra-vaginal preparations), megestrol acetate, or selective estrogen-receptor modulators (e.g., raloxifene)\n* No other concurrent investigational or anticancer agents\n* Concurrent antiangiogenic agents allowed\n* Concurrent bisphosphonates allowed",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}